Value2021202220232024TTMSelling/general/admin expenses25.12 M6.39 M39.84 M29.67 M36.24 MResearch & development20.37 M42.35 M44.87 M42.24 M29.94 MOperating income45.22 M4.04 M83.91 M67.97 M82.38 MNon-Operating Income, Total5.92 M4.89 M7.39 M6.74 M6.32 MInterest expense, net of interest capitalized2.67 M19 K28 K53 K50 KNon-Operating Income, excl. Interest Expenses2.92 M4.3 M6.28 M6.55 M5.51 MUnusual income/expense332 K567 K1.08 M135 K759 KPretax income64.93 M850 K76.52 M61.23 M76.06 MEquity in earnings—————Taxes28 K4.47 M3.08 M44 K115 KNon-controlling/minority interest247 K21 K100 K109 K68 KAfter tax other income/expense—————Net income before discontinued operations50.87 M5.34 M73.35 M61.07 M75.88 MDiscontinued operations—————Net income50.87 M5.34 M73.35 M61.07 M75.88 MDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders50.87 M5.34 M73.35 M61.07 M75.88 MBasic earnings per share (Basic EPS)-1.960.14-1.91-1.55-1.88Diluted earnings per share (Diluted EPS)-1.960.14-1.91-1.55-1.88Average basic shares outstanding25.89 M37.25 M38.39 M39.35 M160.62 MDiluted shares outstanding25.89 M38.17 M38.39 M39.35 M160.62 MEBITDA—————EBIT—————Cost of revenue—————Other cost of goods sold—————Depreciation & amortization (cash flow)602 K4.32 M5.43 M5.8 M6.36 M
Barinthus Biotherapeutics plc - American Depositary Shares
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.